The global market for obesity drugs is soaring, yet Lilly has a dominant market share.
July 30 (Reuters) - Drugmaker Eli Lilly and privately held contract manufacturer Resilience will invest $750 million to ...
Novo Nordisk and Eli Lilly compete in the same blockbuster drug class, yet their 2026 earnings tell dramatically different ...
Cathie Wood is loading up on shares of a biotech that could be one of the first entrants to the psychedelics market.
Eli Lilly (LLY-0.87%) brought in $19.8 billion in revenue in the first quarter of 2026, and most of it can be traced back to ...
Novo alleges Lilly compared the highest approved doses of its medicines with lower doses of Novo’s Wegovy and Ozempic while ...
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. SAN DIEGO — Riding high on the success of its blockbuster weight loss drug, Eli ...
There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of ...
Eli Lilly has doubled down on its partnership with CDMO Resilience as the companies embark on a $750 million investment to ...
The maker of Ozempic and Wegovy says its competitor is misleading consumers by citing outdated weight-loss data in ...
Eli Lilly will acquire psychedelic drugmaker AtaiBeckley for $2.8 billion up front, the company said Thursday, as momentum ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results